{"id":449,"date":"2026-09-04T12:16:16","date_gmt":"2026-09-04T10:16:16","guid":{"rendered":"https:\/\/reborn-peptides.com\/knowledge\/gh-secretagogues\/"},"modified":"2026-09-04T12:16:16","modified_gmt":"2026-09-04T10:16:16","slug":"gh-secretagogues","status":"publish","type":"page","link":"https:\/\/reborn-peptides.com\/en\/knowledge\/gh-secretagogues\/","title":{"rendered":"CJC 1295 Ipamorelin \u2014 two substance classes, two receptor pathways"},"content":{"rendered":"

The names cjc 1295 ipamorelin<\/strong> often appear together online, but they refer to two substance classes associated with two different receptors. This entry is limited to that material distinction. The paired wording names two materials, not one substance. CJC-1295 is not part of the Reborn Peptides range and is mentioned solely to distinguish the materials. The material described here is for laboratory research use only. It is not for human or veterinary use and is not an approved medicinal product. Information about research models is not use guidance.<\/p>\n

Where the collective term comes from<\/h2>\n

A secretagogue is first a term of derivation, not a claim of universally established function. It denotes a compound that triggers the release of a hormone from tissue in a defined model system. The full term growth hormone secretagogue<\/strong> names growth hormone as the research subject. It gives rise to the abbreviation GHS and also explains the origin of the receptor name GHSR.<\/p>\n

The collective label specifies neither one chemical structure nor a single receptor pathway. Substances with different sequences, derivations and receptor families may therefore be discussed under it. Classification depends on the particular compound and the model qualifier under investigation. A class name cannot replace a substance record or experimental evidence for a described signalling pathway. It organises research vocabulary and material names; supportable statements must follow from compound structure, documented receptor association and the limits of the model system. Thus, ipamorelin cjc 1295<\/strong> remains a pairing of two material names, not one sequence or receptor route.<\/p>\n

Ipamorelin: a pentapeptide with a documented structure<\/h2>\n

The ipamorelin peptide<\/strong> is a pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Its five building blocks include modified amino-acid residues, and C-terminal amidation forms part of the structural designation. It emerged from a compound series lacking the central Ala-Trp dipeptide of GHRP-1. This derivation places Ipamorelin structurally in a GHRP-related series without equating it with other members.<\/p>\n

In the cited research, GH release was reported in primary rat pituitary cells in vitro, in anaesthetised rats in an animal model and in pigs in an animal model. The assignment to a GHRP-like receptor rather than the GHRH receptor rests on one of those systems: the pharmacological profiling with GHRP and GHRH antagonists is reported for the in vitro cell system. The two animal models report the release itself, not the antagonist-supported differentiation of the pathway. The assignment therefore rests on the receptor route observed in those particular systems, not merely on similar naming. In later nomenclature, the GHRP-like receptor belongs to the ghrelin receptor family.<\/p>\n

In the pig animal model, FSH, LH, PRL and TSH remained unaffected for all tested substances. ACTH and cortisol were the distinguishing measured variables: GHRP-6 and GHRP-2 increased their plasma levels, whereas Ipamorelin did not release ACTH or cortisol at levels significantly different from those after GHRH stimulation. The source’s selectivity wording and its historical description as the \u201cfirst selective\u201d compound rest on that distinction in the named model. They do not establish a general property beyond those experimental arrangements.<\/p>\n

CJC-1295: the other substance class<\/h2>\n

CJC-1295 is classified by nomenclature as a GHRH-derived analogue of the GRF 1-29 fragment. That derivation points to the GHRH receptor, a different pathway from the GHRP or ghrelin receptor. The circulating distinction between \u201cwith DAC\u201d and \u201cwithout DAC,\u201d also searched as cjc 1295 no dac ipamorelin<\/strong>, denotes a chemical modification rather than two levels of action.<\/p>\n

Sermorelin is another GHRH-derived nomenclature example. In a strictly material-focused sermorelin vs ipamorelin<\/strong> distinction, the former name refers to a GHRH-derived example, whereas Ipamorelin comes from a GHRP-related compound series. This is a classification contrast, not a ranking.<\/p>\n

Jett\u00e9 2005 classified CJC-1295 as an hGRF(1-29) analogue and described its albumin-binding modification in Endocrinology<\/em> (PMID 15817669; model qualifier: cultured rat pituitary cells, in vitro, and male Sprague-Dawley rats, animal model). DAC is the abbreviation commonly used for that chemical binding modification, not a separate level of action.<\/p>\n

Why the two should not be combined<\/h2>\n

One compound is a pentapeptide from a GHRP-related series. The other is named as a GHRH-fragment analogue. Their different derivations lead to different receptor-family assignments: the GHRP or ghrelin receptor on one side and the GHRH receptor on the other. A broad shared label does not erase these material differences. Reading cjc 1295 ipamorelin<\/strong> as one entity assumes a chemical commonality that their sequences and derivations do not provide.<\/p>\n

Laboratory documentation consequently requires separate substance records. Sequence, identity features and chemical modifications must remain clearly assigned to the compound named. The same applies to batch documents: a Certificate of Analysis<\/a> describes a specific batch of a specific material and cannot be transferred to a differently derived compound. Separation preserves identity, traceability and unambiguous source attribution; it does not create a hierarchy or recommendation.<\/p>\n

What was measured in the models<\/h2>\n

Raun 1998 reported primary rat pituitary cells in vitro, anaesthetised rats in an animal model and pigs in an animal model in Eur J Endocrinol<\/em> (PMID 9849822; model qualifier: primary rat pituitary cells, in vitro; anaesthetised rats, animal model; pigs, animal model; DOI 10.1530\/eje.0.1390552). Across those models the authors described material structure and derivation from the compound series; the antagonist-supported differentiation of the receptor pathway is reported for the in vitro cell system. In the pig animal model, FSH, LH, PRL and TSH were reported as unaffected measured variables for all tested substances; the selectivity wording used in the paper rests instead on ACTH and cortisol, which increased with GHRP-6 and GHRP-2 but not with Ipamorelin at levels significantly different from those after GHRH stimulation.<\/p>\n

Gobburu 1999 described PK\/PD modelling in healthy male volunteers in Pharm Res<\/em> (PMID 10496658; model qualifier: healthy male volunteers, PK\/PD modelling; DOI 10.1023\/a:1018955126402). In that modelling, between-participant variability was greater for pharmacodynamic parameters than for pharmacokinetic parameters. PK\/PD modelling describes the time course of measured variables and does not demonstrate practical value.<\/p>\n

Jett\u00e9 2005 described CJC-1295 as a tetrasubstituted form of hGRF(1-29) bearing a C-terminally added N-epsilon-3-maleimidopropionamide derivative of lysine in Endocrinology<\/em> (PMID 15817669; model qualifier: cultured rat pituitary cells, in vitro, and male Sprague-Dawley rats, animal model; DOI 10.1210\/en.2004-1286). In those cell-culture and rat systems, the maleimide group served to conjugate with the free thiol at Cys34 of serum albumin, and CJC-1295 was assigned to the GRF receptor, meaning the GHRH receptor. This material description from cell culture and an animal model makes no statement about people.<\/p>\n

For methodological context on these boundaries, see in vitro and in vivo study models<\/a>.<\/p>\n

What the literature does not establish<\/h2>\n

Findings from cell systems and animal models do not support statements about people. Likewise, a pharmacokinetic and pharmacodynamic description is not evidence of practical value. An observation concerning one compound does not pass to a differently derived compound, even when both appear beneath a broad collective term. An Ipamorelin finding therefore says nothing about CJC-1295, even where both are listed together as cjc 1295 ipamorelin.<\/p>\n

In the literature reviewed here, cjc 1295 ipamorelin<\/strong> is not presented as one joint research subject: the Ipamorelin papers describe Ipamorelin, while the CJC-1295 paper describes CJC-1295. The model qualifier, substance identity and measured variable delimit what can be inferred from each publication. Background terminology is available in peptide research basics<\/a>.<\/p>\n

Classification in the laboratory context<\/h2>\n

Identity and purity belong to the specific batch and must be documented in a batch-linked analytical record. Information about the Ipamorelin research compound<\/a> remains separate from the CJC-1295 discussion on this page. Keeping material description, batch evidence and literature context apart makes each evidence chain traceable.<\/p>\n

Sources<\/h2>\n